2025-12-24 - Analysis Report
Okay, here's the analysis of Natera Inc. (NTRA), based on the information provided.

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Natera Inc. is a diagnostics company specializing in cell-free DNA (cfDNA) testing for reproductive health, oncology, and organ health.
*   **Cumulative Return:**
    *   NTRA: 137.67%
    *   S&P 500 (VOO): 101.15%
*   **Divergence:**
    *   Current: 36.5
    *   Relative Divergence: 47.5

**Analysis:** NTRA has outperformed the S&P 500 significantly over the analyzed period. The current divergence suggests it's currently in the middle of its historical divergence range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha  | Beta | Cap(B) |
|------------|-------|-------|--------|------|--------|
| 2015-2017  | -10.0% | 70.1% | -34.0% | -0.2 | 1.3    |
| 2016-2018  | 22.0%  | 80.0% | 6.0%   | 0.1  | 2.0    |
| 2017-2019  | 50.0%  | 80.0% | 28.0%  | 1.0  | 4.8    |
| 2018-2020  | 186.0% | 80.5% | 163.0% | 1.1  | 14.1   |
| 2019-2021  | 96.0%  | 80.5% | 49.0%  | 1.6  | 13.2   |
| 2020-2022  | -77.0% | 80.5% | -76.0% | 0.1  | 5.7    |
| 2021-2023  | -194.0%| 76.6% | -195.0%| -1.1 | 8.9    |
| 2022-2024  | 8.0%   | 76.6% | -13.0% | -1.2 | 22.4   |
| 2023-2025  | 165.0% | 76.6% | 99.0%  | 0.1  | 32.8   |

*   **CAGR (Compound Annual Growth Rate):** Fluctuates significantly, showing periods of strong growth and sharp declines.
*   **MDD (Maximum Drawdown):** Consistently high, indicating significant volatility and risk.
*   **Alpha:** Measures outperformance relative to the benchmark.  Large positive alpha values (e.g., 2018-2020) indicate significant outperformance. Negative values indicate underperformance.
*   **Beta:** Measures volatility relative to the market. A beta around 1 suggests the stock moves similarly to the market. Betas significantly above 1 (e.g., 2019-2021) suggest higher volatility than the market. Negative betas suggest the stock moves inversely to the market.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 231.96
*   **Last Market Data:**
    *   Price: 235.4
    *   Previous Close: 235.57
    *   Change: -0.07
*   **Moving Averages:**
    *   5-day SMA: 227.60
    *   20-day SMA: 234.50
    *   60-day SMA: 203.50

**Analysis:** The stock price is currently trading below its 20-day SMA, but above its 60-day SMA. The 5-day SMA is below the 20-day, suggesting a short-term downward trend. The very recent price change is slightly negative.

**3) RSI, PPO, and Other Indicators**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI (Relative Strength Index):** 42.84 (Neutral, neither overbought nor oversold)
*   **PPO (Percentage Price Oscillator):** -1.26 (Slightly bearish, indicating short-term weakness)
*   **Hybrid Signal:** 100% Buy (Very Safe - MRI:0.90)
*   **Recent Divergence Change:** -0.1 (Short-term decline)
*   **Expected Return:** -49.9% (Negative, suggesting potential underperformance compared to the S&P 500 over a long-term investment horizon)

**Analysis:** The MRI suggests a medium level of investment recommendation. The RSI is neutral. The PPO suggests a slight short-term downward trend. The hybrid signal suggests a 100% buy with monthly invest 0.8% of total investment ($1,000.00). However, the concerning point is the negative expected return.

**4) Recent News & Significant Events**

*   **Positive:**
    *   Investor mentioning NTRA as one of their current picks.
    *   Canaccord Genuity and J.P. Morgan raising price targets, citing Signatera momentum.
    *   Orion Portfolio Solutions LLC buying shares.
    *   Upcoming presentation at a health conference.
*   **Neutral/Informative:**
    *   Discussion of Natera's stock opinions on Foresight Acquisition and Signatera data.

**Analysis:** Recent news is mostly positive, with analysts raising price targets and institutional investors taking positions. The upcoming presentation at a health conference could be a catalyst.

**4-2) Analyst Opinions**

*   **Consensus:** Strong Buy (Mean: 1.47)
*   **Target Price:**
    *   Average: 246.26
    *   High: 285.00
    *   Low: 186.00
*   **Recent Rating Changes:** Not provided.

**Analysis:** Analyst sentiment is strongly positive, with a strong buy consensus and an average target price above the current price.

**5) Recent Earnings Analysis**

| 날짜       | EPS    | 매출      |
|------------|--------|-----------|
| 2025-11-07 | -0.64  | 0.59 B$   |
| 2025-08-08 | -0.74  | 0.55 B$   |
| 2025-05-09 | -0.50  | 0.50 B$   |
| 2024-11-12 | -0.26  | 0.44 B$   |
| 2025-11-07 | -0.26  | 0.44 B$   |

**Analysis:** Natera is currently not profitable, with negative EPS values for all reported quarters. Revenue is growing consistently, but losses persist. The latest EPS figure is quite high which means that profitability is not being realized.

**6) Financial Information (Revenue, Profitability, Capital)**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-09-30 | $0.59B  | 64.91%        |
| 2025-06-30 | $0.55B  | 63.41%        |
| 2025-03-31 | $0.50B  | 63.12%        |
| 2024-12-31 | $0.48B  | 62.94%        |
| 2024-09-30 | $0.44B  | 61.79%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE     |
|------------|---------|---------|
| 2025-09-30 | $1.25B  | -6.99%  |
| 2025-06-30 | $1.25B  | -8.10%  |
| 2025-03-31 | $1.24B  | -5.40%  |
| 2024-12-31 | $1.20B  | -4.50%  |
| 2024-09-30 | $0.88B  | -3.60%  |

**Analysis:** Revenue and profit margins are growing. However, the Return on Equity (ROE) is negative, reinforcing the lack of profitability. Equity has been increasing over the period.

**7) Comprehensive Analysis (Summary)**

Natera (NTRA) is a high-growth, high-risk stock. It has significantly outperformed the S&P 500 historically, but also exhibits substantial volatility and a high maximum drawdown. Recent news is largely positive, with analyst upgrades and institutional buying. Analyst consensus is a strong buy, and the average price target is above the current price. However, the company is currently unprofitable, with negative EPS and ROE, even though Revenue and Profit margins are growing. The negative expected return (-49.9%) is a significant cause for concern. The short-term technical indicators are mixed, but slightly bearish. MRI suggest medium investment opportunity, but the hybrid signal recommends a 100% buy position.

**Investment Recommendation:**
Due to the volatility, unprofitability and negative excess return, a conservative position should be kept in mind. Keep a position that does not affect the overall portfolio.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.